CoChat

The Evolution of Insulin and How it Informs Therapy and Treatment Choices

Open access

The DOI matches its Crossref record; 79 of the 82 references it cites were found in a registry or an index.

Abstract

Insulin has been available for the treatment of diabetes for almost a century, and the variety of insulin choices today represents many years of discovery and innovation. Insulin has gone from poorly defined extracts of animal pancreata to pure and precisely controlled formulations that can be prescribed and administered with high accuracy and predictability of action. Modifications of the insulin formulation and of the insulin molecule itself have made it possible to approximate the natural endogenous insulin response. Insulin and insulin formulations had to be designed to produce either a constant low basal level of insulin or the spikes of insulin released in response to meals. We discuss how the biochemical properties of endogenous insulin were exploited to either shorten or extend the time-action profiles of injectable insulins by varying the pharmacokinetics (time for appearance of insulin in the blood after injection) and pharmacodynamics (time-dependent changes in blood sugar after injection). This has resulted in rapid-acting, short-acting, intermediate-acting, and long-acting insulins, as well as mixtures and concentrated formulations. An understanding of how various insulins and formulations were designed to solve the challenges of insulin replacement will assist clinicians in meeting the needs of their individual patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/endrev/bnaa015

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical Abstract
Graphical Abstract CC BY · PubMed Central
Figure 1. Timeline of insulin development with approximate historical dates. Abbreviations: NPH, neutral protamine Hagedorn; rDNA, recombinant DNA; U = units.
Figure 1. Timeline of insulin development with approximate historical dates. Abbreviations: NPH, neutral protamine Hagedorn; rDNA, recombinant DNA; U = units.CC BY · PubMed Central
Figure 2. Structure of human insulin. A: Amino acid sequence of human insulin. B: Three-dimensional structure of insulin monomer (A-chain in purple; B-chain in green; protein data bank [PDB] ID = 1LPH), insulin dimer (PDB ID = 1LPH), and insulin hexamer (comprised of 3 dimers and 2 Zn2+) (PDB ID = 2INS). (https://www.rcsb.org/pdb/static.do?p=general_information/about_pdb/index.html); 1LPH, 2INS=PDB ID for respective structures)
Figure 2. Structure of human insulin. A: Amino acid sequence of human insulin. B: Three-dimensional structure of insulin monomer (A-chain in purple; B-chain in green; protein data bank [PDB] ID = 1LPH), insulin dimer (PDB ID = 1LPH), and insulin hexamer (comprised of 3 dimers and 2 Zn2+) (PDB ID = 2INS). (https://www.rcsb.org/pdb/static.do?p=general_information/about_pdb/index.html); 1LPH, 2INS=PDB ID for respective structures)CC BY · PubMed Central
Figure 3. Role of insulin hexamers in insulin PK. A: Insulin hexamers in pancreatic β-cells disassemble into monomers upon dilution in the blood stream and diffuse into tissues where they bind to insulin receptors on target cells. B: (1) Regular insulin is formulated as hexamers in the presence of zinc; (2) insulin is injected into the SC space; (3) insulin hexamers dissociate into dimers then monomers in the SC space; (4) the size of the monomers permits absorption across the microvascular endothelium into the blood. C: Pharmacokinetics profile of endogenous insulin (blue line) following a meal in healthy subjects (n = 6), and of exogenous insulin (red line) when human regular insulin (0.1 U/kg SC) was injected 5 minutes before the meal in subjects with type 1 diabetes (n = 6). Data from Pampanelli S, Torlone E, Ialli C, Del Sindaco P, Ciofetta M, Lepore M, et al. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Diabetes Care. 1995;18(11):1452–1459.
Figure 3. Role of insulin hexamers in insulin PK. A: Insulin hexamers in pancreatic β-cells disassemble into monomers upon dilution in the blood stream and diffuse into tissues where they bind to insulin receptors on target cells. B: (1) Regular insulin is formulated as hexamers in the presence of zinc; (2) insulin is injected into the SC space; (3) insulin hexamers dissociate into dimers then monomers in the SC space; (4) the size of the monomers permits absorption across the microvascular endothelium into the blood. C: Pharmacokinetics profile of endogenous insulin (blue line) following a meal in healthy subjects (n = 6), and of exogenous insulin (red line) when human regular insulin (0.1 U/kg SC) was injected 5 minutes before the meal in subjects with type 1 diabetes (n = 6). Data from Pampanelli S, Torlone E, Ialli C, Del Sindaco P, Ciofetta M, Lepore M, et al. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Diabetes Care. 1995;18(11):1452–1459.CC BY · PubMed Central
Figure 4. Pharmacokinetics and PD profiles, explained. A: Pharmacokinetics profile: insulin concentration versus time after injection. B: Pharmacodynamics profile: GIR versus time after insulin injection. Abbreviations: AUC, area under the curve; Cmax, maximum concentration reached; Gtotal, total amount of glucose infused; Rmax, maximum rate of glucose infusion; Tmax, time to reach Cmax; TRmax, time to reach Rmax.
Figure 4. Pharmacokinetics and PD profiles, explained. A: Pharmacokinetics profile: insulin concentration versus time after injection. B: Pharmacodynamics profile: GIR versus time after insulin injection. Abbreviations: AUC, area under the curve; Cmax, maximum concentration reached; Gtotal, total amount of glucose infused; Rmax, maximum rate of glucose infusion; Tmax, time to reach Cmax; TRmax, time to reach Rmax.CC BY · PubMed Central
Figure 5. Rapid-acting insulins. A: Amino acid changes in the structures of rapid-acting insulin analogs. B: Quicker hexamer dissolution in the interstitial space of insulin lispro compared to regular insulin. C: Pharmacokinetics profile of insulin lispro compared to human regular insulin, showing a faster onset of action and peak of action, and a shorter duration of action when 0.075 U/kg of insulin was injected 10 minutes before a 50 g 13C-glucose load after an overnight fast (N = 8 subjects with type 2 diabetes). D: Pharmacodynamics profile from the same study, showing 13C-labeled serum glucose concentration during the study, corrected for 3H-labeled baseline glucose. Data for (C) and (D) from Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti MC, Avogaro A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes. 1999;48(1):99–105.
Figure 5. Rapid-acting insulins. A: Amino acid changes in the structures of rapid-acting insulin analogs. B: Quicker hexamer dissolution in the interstitial space of insulin lispro compared to regular insulin. C: Pharmacokinetics profile of insulin lispro compared to human regular insulin, showing a faster onset of action and peak of action, and a shorter duration of action when 0.075 U/kg of insulin was injected 10 minutes before a 50 g 13C-glucose load after an overnight fast (N = 8 subjects with type 2 diabetes). D: Pharmacodynamics profile from the same study, showing 13C-labeled serum glucose concentration during the study, corrected for 3H-labeled baseline glucose. Data for (C) and (D) from Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti MC, Avogaro A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes. 1999;48(1):99–105.CC BY · PubMed Central
Figure 6. Faster-acting insulin aspart. A: Pharmacokinetics and PD profiles of faster aspart compared to aspart in 43 subjects with type 1 diabetes. Euglycemic clamp studies were conducted in a crossover fashion such that each subject was tested with 3 different doses of each insulin. The results for the 0.4 U/kg dose are shown. Data from Heise T, Stender-Petersen K, Hovelmann U, Jacobsen JB, Nosek L, Zijlstra E, et al. Pharmacokinetic and pharmacodynamic properties of faster-acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus. Clin Pharmacokinet. 2017;56(6):649–660.
Figure 6. Faster-acting insulin aspart. A: Pharmacokinetics and PD profiles of faster aspart compared to aspart in 43 subjects with type 1 diabetes. Euglycemic clamp studies were conducted in a crossover fashion such that each subject was tested with 3 different doses of each insulin. The results for the 0.4 U/kg dose are shown. Data from Heise T, Stender-Petersen K, Hovelmann U, Jacobsen JB, Nosek L, Zijlstra E, et al. Pharmacokinetic and pharmacodynamic properties of faster-acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus. Clin Pharmacokinet. 2017;56(6):649–660.CC BY · PubMed Central
Figure 7. Afrezza® inhaled insulin. A: Pharmacokinetics profile (baseline corrected serum insulin concentration) of inhaled Afrezza® (8 units) compared to injected insulin lispro (8 units) in 12 subjects with type 1 diabetes. B: Pharmacodynamics profile of inhaled Afrezza® (8 units) compared to injected insulin lispro (10 units) in 25 subjects with type 1 diabetes. Both studies were euglycemic clamp studies. Data from Heinemann L, Baughman R, Boss A, Hompesch M. Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin. J Diabetes Sci Technol. 2017;11(1):148–156.
Figure 7. Afrezza® inhaled insulin. A: Pharmacokinetics profile (baseline corrected serum insulin concentration) of inhaled Afrezza® (8 units) compared to injected insulin lispro (8 units) in 12 subjects with type 1 diabetes. B: Pharmacodynamics profile of inhaled Afrezza® (8 units) compared to injected insulin lispro (10 units) in 25 subjects with type 1 diabetes. Both studies were euglycemic clamp studies. Data from Heinemann L, Baughman R, Boss A, Hompesch M. Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin. J Diabetes Sci Technol. 2017;11(1):148–156.CC BY · PubMed Central
Figure 8. Neutral protamine hagedorn insulin. A: Pharmacokinetics and PD profiles of human NPH insulin (n = 6; 25 units SC) compared to human regular insulin (n = 10; 10 units SC) in healthy men. Subjects were fasted overnight prior to injection and kept under a euglycemic clamp for 24 hours or 12 hours, respectively. Data from Woodworth JR, Howey DC, Bowsher RR. Establishment of time-action profiles for regular and NPH insulin using pharmacodynamic modeling. Diabetes Care. 1994;17(1):64–69.
Figure 8. Neutral protamine hagedorn insulin. A: Pharmacokinetics and PD profiles of human NPH insulin (n = 6; 25 units SC) compared to human regular insulin (n = 10; 10 units SC) in healthy men. Subjects were fasted overnight prior to injection and kept under a euglycemic clamp for 24 hours or 12 hours, respectively. Data from Woodworth JR, Howey DC, Bowsher RR. Establishment of time-action profiles for regular and NPH insulin using pharmacodynamic modeling. Diabetes Care. 1994;17(1):64–69.CC BY · PubMed Central
Figure 9. Insulin glargine. A: Amino acid structure of insulin glargine. B: Mechanism of protraction of insulin glargine: pH-induced precipitation at the SC space. C and D: Pharmacokinetics and PD profiles of insulin glargine U-100 compared to NPH insulin (each 0.3 U/kg) from a euglycemic clamp study in 20 subjects with type 1 diabetes. Data from Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49(12):2142–2148.
Figure 9. Insulin glargine. A: Amino acid structure of insulin glargine. B: Mechanism of protraction of insulin glargine: pH-induced precipitation at the SC space. C and D: Pharmacokinetics and PD profiles of insulin glargine U-100 compared to NPH insulin (each 0.3 U/kg) from a euglycemic clamp study in 20 subjects with type 1 diabetes. Data from Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49(12):2142–2148.CC BY · PubMed Central
Figure 10. Nonbioequivalence of U-100 and U-300 glargine. A: Comparison of PK and PD profiles for insulin glargine U-100 and insulin glargine U-300 (0.4 U/kg each) in a euglycemic clamp study at steady state in 18 patients with type 1 diabetes. Data from Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 Units/mL provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units/mL. Diabetes Care. 2015; 38(4):637–643. B: Dose dependence of PK profile of insulin glargine U-300 in a euglycemic clamp study in 24 patients with type 1 diabetes. Data from Center for Drug Evaluation and Research. Clinical Pharmacology Review: Toujeo® insulin glargine. 2014; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206538Orig1s000ClinPharmR.pdf. Accessed May 21, 2019.
Figure 10. Nonbioequivalence of U-100 and U-300 glargine. A: Comparison of PK and PD profiles for insulin glargine U-100 and insulin glargine U-300 (0.4 U/kg each) in a euglycemic clamp study at steady state in 18 patients with type 1 diabetes. Data from Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 Units/mL provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units/mL. Diabetes Care. 2015; 38(4):637–643. B: Dose dependence of PK profile of insulin glargine U-300 in a euglycemic clamp study in 24 patients with type 1 diabetes. Data from Center for Drug Evaluation and Research. Clinical Pharmacology Review: Toujeo® insulin glargine. 2014; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206538Orig1s000ClinPharmR.pdf. Accessed May 21, 2019.CC BY · PubMed Central
Figure 11. Insulin detemir. A: Amino acid structure of insulin detemir. B: Mechanism of protraction: di-hexamer formation in the SC space and binding to albumin. C and D: Pharmacokinetics and PD profiles of insulin glargine (n = 12, blue line) and insulin detemir (n = 12, red line) at steady state, from euglycemic clamp study following SC injection of 0.35 U/kg in patients with type 1 diabetes. Data from Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care. 2007; 30(10):2447–2452.
Figure 11. Insulin detemir. A: Amino acid structure of insulin detemir. B: Mechanism of protraction: di-hexamer formation in the SC space and binding to albumin. C and D: Pharmacokinetics and PD profiles of insulin glargine (n = 12, blue line) and insulin detemir (n = 12, red line) at steady state, from euglycemic clamp study following SC injection of 0.35 U/kg in patients with type 1 diabetes. Data from Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care. 2007; 30(10):2447–2452.CC BY · PubMed Central
Figure 12. Insulin degludec. A: Amino acid structure of insulin degludec. B: Mechanism of sustained release exploits multihexamer formation and binding to albumin. C and D: Comparison of PK and PD of insulin degludec (N = 22; 0.4 U/kg) and insulin glargine (N = 22; 0.44 U/kg) at steady state from a euglycemic clamp study in subjects with type 1 diabetes. Data from Heise T, Hovelmann U, Nosek L, Hermanski L, Bottcher SG, Haahr H. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol. 2015;11(8):1193–1201.
Figure 12. Insulin degludec. A: Amino acid structure of insulin degludec. B: Mechanism of sustained release exploits multihexamer formation and binding to albumin. C and D: Comparison of PK and PD of insulin degludec (N = 22; 0.4 U/kg) and insulin glargine (N = 22; 0.44 U/kg) at steady state from a euglycemic clamp study in subjects with type 1 diabetes. Data from Heise T, Hovelmann U, Nosek L, Hermanski L, Bottcher SG, Haahr H. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol. 2015;11(8):1193–1201.CC BY · PubMed Central
Figure 13. Premix insulins. A: Pharmacodynamics profiles for a 0.3 U/kg dose of an insulin premix (NPH insulin 70%, human insulin 30%) and a 0.3 U/kg dose of human regular insulin from a euglycemic clamp study in 18 healthy subjects. Data from Eli Lilly and Company. Humulin® 70/30 Prescribing Information. 2018; http://pi.lilly.com/us/HUMULIN-7030-USPI.pdf. Accessed April 4, 2019. B: Pharmacodynamics profiles of human insulin premix (NPH insulin 70%, human insulin 30%; 0.3 U/kg) (N = 18) or an analog insulin premix (NPL insulin 75%, insulin lispro 25%; 0.3 U/kg) (N = 30) from a euglycemic clamp study in healthy subjects. Data from Heise T, Weyer C, Serwas A, Heinrichs S, Osinga J, Roach P, et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care. 1998;21(5):800–803.
Figure 13. Premix insulins. A: Pharmacodynamics profiles for a 0.3 U/kg dose of an insulin premix (NPH insulin 70%, human insulin 30%) and a 0.3 U/kg dose of human regular insulin from a euglycemic clamp study in 18 healthy subjects. Data from Eli Lilly and Company. Humulin® 70/30 Prescribing Information. 2018; http://pi.lilly.com/us/HUMULIN-7030-USPI.pdf. Accessed April 4, 2019. B: Pharmacodynamics profiles of human insulin premix (NPH insulin 70%, human insulin 30%; 0.3 U/kg) (N = 18) or an analog insulin premix (NPL insulin 75%, insulin lispro 25%; 0.3 U/kg) (N = 30) from a euglycemic clamp study in healthy subjects. Data from Heise T, Weyer C, Serwas A, Heinrichs S, Osinga J, Roach P, et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care. 1998;21(5):800–803.CC BY · PubMed Central
Figure 14. Ryzodeg® (insulin aspart 30%, insulin degludec 70%). Pharmacodynamics profiles of single doses of Ryzodeg® and Novolog® (insulin aspart) at 0.6 U/kg from a euglycemic clamp study in 31 subjects with type 1 diabetes. Also shown for comparison is the PD profile of Ryzodeg® 0.6 U/kg from a euglycemic clamp study in 22 subjects with type 1 diabetes taking insulin degludec for 5 days prior to the study to achieve steady state (SS). Data from Heise T, Nosek L, Klein O, Coester H, Svendsen AL, Haahr H. Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus. Diab Obes Metab. 2015;17(7):659–664.
Figure 14. Ryzodeg® (insulin aspart 30%, insulin degludec 70%). Pharmacodynamics profiles of single doses of Ryzodeg® and Novolog® (insulin aspart) at 0.6 U/kg from a euglycemic clamp study in 31 subjects with type 1 diabetes. Also shown for comparison is the PD profile of Ryzodeg® 0.6 U/kg from a euglycemic clamp study in 22 subjects with type 1 diabetes taking insulin degludec for 5 days prior to the study to achieve steady state (SS). Data from Heise T, Nosek L, Klein O, Coester H, Svendsen AL, Haahr H. Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus. Diab Obes Metab. 2015;17(7):659–664.CC BY · PubMed Central
Figure 15. Test for bioequivalence of 2 insulins. Pharmacokinetics parameters of the test insulin (B), usually AUC and Cmax (peak concentration reached), must lie within a prespecified range of the reference insulin (A) to be considered bioequivalent when administered at the same molar dose under the same conditions.
Figure 15. Test for bioequivalence of 2 insulins. Pharmacokinetics parameters of the test insulin (B), usually AUC and Cmax (peak concentration reached), must lie within a prespecified range of the reference insulin (A) to be considered bioequivalent when administered at the same molar dose under the same conditions.CC BY · PubMed Central
Figure 16. Bioequivalent insulins. A: Comparison of PK and PD profiles for insulin lispro U-100 and insulin lispro U-200 from a euglycemic clamp study in 38 healthy subjects (SC administration of 20 U). Data from de la Pena A, Seger M, Soon D, Scott AJ, Reddy SR, Dobbins MA, et al. Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL. Clin Pharmacol Drug Dev. 2016;5(1):69–75. B: Comparison of PK and PD profiles for insulin degludec U-100 and insulin degludec U-200 from a euglycemic clamp study at steady state (N = 33 patients with type 1 diabetes; 0.4 U/kg given once daily with insulin aspart at mealtimes). Data from Korsatko S, Deller S, Koehler G, Mader JK, Neubauer K, Adrian CL, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultralong-acting insulin degludec. Clin Drug Investig. 2013;33(7):515–521.
Figure 16. Bioequivalent insulins. A: Comparison of PK and PD profiles for insulin lispro U-100 and insulin lispro U-200 from a euglycemic clamp study in 38 healthy subjects (SC administration of 20 U). Data from de la Pena A, Seger M, Soon D, Scott AJ, Reddy SR, Dobbins MA, et al. Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL. Clin Pharmacol Drug Dev. 2016;5(1):69–75. B: Comparison of PK and PD profiles for insulin degludec U-100 and insulin degludec U-200 from a euglycemic clamp study at steady state (N = 33 patients with type 1 diabetes; 0.4 U/kg given once daily with insulin aspart at mealtimes). Data from Korsatko S, Deller S, Koehler G, Mader JK, Neubauer K, Adrian CL, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultralong-acting insulin degludec. Clin Drug Investig. 2013;33(7):515–521.CC BY · PubMed Central
Figure 17. Nonbioequivalent insulins. Pharmacokinetics profiles (A) and PD profiles (B) of 2 doses each of human regular U-100 and U-500 insulins from a euglycemic clamp study in 24 healthy obese subjects. Data from de la Pena A, Riddle M, Morrow LA, Jiang HH, Linnebjerg H, Scott A, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011;34(12):2496–2501.
Figure 17. Nonbioequivalent insulins. Pharmacokinetics profiles (A) and PD profiles (B) of 2 doses each of human regular U-100 and U-500 insulins from a euglycemic clamp study in 24 healthy obese subjects. Data from de la Pena A, Riddle M, Morrow LA, Jiang HH, Linnebjerg H, Scott A, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011;34(12):2496–2501.CC BY · PubMed Central
Figure 18. Example of similar PK and PD profiles of biosimilar insulin glargine products (Basaglar® and Lantus®). Healthy subjects (n = 80) received 0.5 units/kg of insulin in a euglycemic clamp study. Data are mean and standard deviation. Abbreviations: EU IGlar, Lantus®; LY IGlar, Basaglar®. Data from Linnebjerg H, Lam EC, Seger ME, Coutant D, Chua L, Chong CL, et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus® insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care. 2015;38(12):2226–2233.
Figure 18. Example of similar PK and PD profiles of biosimilar insulin glargine products (Basaglar® and Lantus®). Healthy subjects (n = 80) received 0.5 units/kg of insulin in a euglycemic clamp study. Data are mean and standard deviation. Abbreviations: EU IGlar, Lantus®; LY IGlar, Basaglar®. Data from Linnebjerg H, Lam EC, Seger ME, Coutant D, Chua L, Chong CL, et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus® insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care. 2015;38(12):2226–2233.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 288

Metadata

Authors
Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J., & Wright, E. E.
Affiliations
  • University of Washington (US)
  • Eli Lilly (United States) (US)
  • Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California
  • Charlotte Area Health Education Center, Charlotte, North Carolina
Corresponding author
Hirsch, Irl B
Venue
Endocrine Reviews
Published
2020-05-12
Volume
41
Issue
5
Pages
733-755
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W3024580742
Cited by
237
References
82
Citations by year
2026: 25 · 2025: 50 · 2024: 37 · 2023: 37 · 2022: 45 · 2021: 38 · 2020: 4
FWCI
4.76
Type
journal article
Language
en
Open access
Locations
  • Endocrine Reviews (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
insulin, insulin formulations, insulin analogues, rapid-acting insulin, long-acting insulin, short-acting insulin, intermediate-acting insulin, insulin mixtures, insulin levels, pharmacokinetics, pharmacodynamics, endogenous insulin, diabetes treatment, insulin replacement therapy
MeSH terms
Diabetes Mellitus, Humans, Hypoglycemic Agents, Insulins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.